Literature DB >> 15313816

High recurrence rates of Basal cell carcinoma after mohs surgery in patients with chronic lymphocytic leukemia.

Khosrow Mehrany1, Roger H Weenig, Mark R Pittelkow, Randall K Roenigk, Clark C Otley.   

Abstract

OBJECTIVES: To estimate and compare the recurrence rates of basal cell carcinoma (BCC) after Mohs surgery in patients with chronic lymphocytic leukemia (CLL) and controls and to evaluate differences among histologic subtypes of BCC.
DESIGN: Retrospective assessment of clinical histories, postoperative notes, and surgical photographs.
SETTING: Tertiary-care institution (Mayo Clinic, Rochester, Minn). PATIENTS: Twenty-four patients with CLL who underwent Mohs surgery for 33 BCCs and 66 controls matched for sex, age, and surgical year who underwent Mohs surgery for BCC of the head and neck from May 1988 through September 1998.
RESULTS: Among the 24 patients with CLL who underwent Mohs surgery for 33 BCCs, there were 4 recurrences. The cumulative incidence of recurrence on a per-tumor basis was 3% at 1 year, 12% at 3 years, and 22% at 5 years. Basal cell carcinoma was 14 times more likely to recur in patients with CLL than in controls (P =.02). Overall, there were no significant differences between patients with CLL and controls in preoperative tumor size (median, 1.6 cm vs 1.4 cm; P =.18) and proportion of aggressive histologic subtypes of BCC (58% vs 41%; P =.12).
CONCLUSIONS: Recurrence rates of BCC are significantly higher after Mohs surgery in patients with CLL. Overall, patients with CLL do not appear to have significantly larger BCCs or more aggressive histologic subtypes of BCC. In patients with CLL, close surveillance is warranted for recurrence of BCC and a decreased threshold is indicated for subsequent biopsies.

Entities:  

Mesh:

Year:  2004        PMID: 15313816     DOI: 10.1001/archderm.140.8.985

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  7 in total

Review 1.  Roles of the immune system in skin cancer.

Authors:  S Rangwala; K Y Tsai
Journal:  Br J Dermatol       Date:  2011-11       Impact factor: 9.302

2.  Increased incidence and recurrence rates of nonmelanoma skin cancer in patients with non-Hodgkin lymphoma: a Rochester Epidemiology Project population-based study in Minnesota.

Authors:  Jerry D Brewer; Tait D Shanafelt; Farzaneh Khezri; Ivette M Sosa Seda; Adeel S Zubair; Christian L Baum; Christopher J Arpey; James R Cerhan; Timothy G Call; Randall K Roenigk; Carin Y Smith; Amy L Weaver; Clark C Otley
Journal:  J Am Acad Dermatol       Date:  2014-12-02       Impact factor: 11.527

Review 3.  [Micrographically controlled surgery. Goals and reality].

Authors:  W Weyers
Journal:  Hautarzt       Date:  2007-09       Impact factor: 0.751

Review 4.  Risk for second nonlymphoid neoplasms in chronic lymphocytic leukemia.

Authors:  Constantin A Dasanu; Doru T Alexandrescu
Journal:  MedGenMed       Date:  2007-11-15

5.  Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes.

Authors:  Ohad Benjamini; Preetesh Jain; Long Trinh; Wei Qiao; Sara S Strom; Susan Lerner; Xuemei Wang; Jan Burger; Alessandra Ferrajoli; Hagop Kantarjian; Susan O'Brien; William Wierda; Zeev Estrov; Michael Keating
Journal:  Leuk Lymphoma       Date:  2014-11-19

6.  Eyelid carcinoma in patients with systemic lymphoma.

Authors:  Debraj Shome; Diana Bell; Bita Esmaeli
Journal:  J Ophthalmic Vis Res       Date:  2010-01

Review 7.  Cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia: a systematic review of the literature.

Authors:  Michela Lai; Riccardo Pampena; Luigi Cornacchia; Giulia Odorici; Alfredo Piccerillo; Giovanni Pellacani; Ketty Peris; Caterina Longo
Journal:  Int J Dermatol       Date:  2021-08-05       Impact factor: 3.204

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.